

Table 1 Summary of results of phase II trials on the effects of filgotinib in treating patients with rheumatoid arthritis

Study	No. patients	Population	Duration	Filgotinib dose	Primary end-points	Secondary end-points	Summary
DARWIN 1	594	MTX-IR	24 weeks	MTX + Placebo MTX + filgotinib 50mg QD MTX + filgotinib 100mg QD MTX+ filgotinib 200mg QD MTX+ filgotinib 25mg BD MTX+ filgotinib 50mg BD MTX+ filgotinib 100mg BD	ACR20 response at week 12	ACR20, ACR50, ACR70 ACR-N DAS28-CRP EULAR response ACR/EULAR remission CDAI, SDAI HAQ-DI	Significant number of patients on filgotinib achieved ACR20 response compared to placebo Filgotinib 100mg QD: 64% Filgotinib 200mg QD: 69% Filgotinib 100mg BD: 79% Placebo: 44%
DARWIN 2	283	MTX-IR	24 weeks	Placebo Filgotinib 50mg QD Filgotinib 100mg QD Filgotinib 200mg QD	ACR20 response at week 12	ACR20, ACR50, ACR70 ACR-N DAS28-CRP EULAR response ACR/EULAR remission CDAI, SDAI, HAQ-DI	Significant number of patients on all filgotinib treatment groups achieved ACR20 response compared to placebo. Filgotinib 50mg QD: 67% Filgotinib 100mg QD: 66% Filgotinib 200mg QD: 73% Placebo: 29%

ACR20%,50%,70%,.: Percentage of improvement in the American College of Rheumatology core set measure, ACR-N: American College of Rheumatology N% improvement, BID: twice a day, CDAI: Clinical Disease Activity Index, DAS28-CRP:Disease Activity Score based on 28

joints and C-reactive protein value, EULAR: European League Against Rheumatism, HAQ-DI: Health Assessment Questionnaire-Disability Index, MTX-IR: resistance to MXT, SDAI: Simplified Disability Index

